Health-related quality of life and economic burden of prurigo nodularis - 17/02/22
Abstract |
Background |
Prurigo nodularis (PN) is an understudied, pruritic inflammatory skin disease. Little is known about the effect of PN on quality of life and its associated economic burden.
Objective |
To quantify the impact of PN on quality of life and its economic implications.
Methods |
A cohort study of PN patients (n = 36) was conducted using the Health Utilities Index Mark 3 questionnaire. Control data from US adults (n = 4187) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Quality-adjusted life year loss and economic costs were estimated by comparing the Health Utilities Index Mark 3 scores of the PN patients with those of the controls.
Results |
The PN patients had lower overall health performance compared to the controls, (mean ± SE, 0.52 ± 0.06 vs 0.86 ± 0.003, respectively, P < .001). In multivariable regression, PN was found to be associated with worse health performance (coefficient −0.34, 95% CI [−0.46 to −0.23]), most prominent in the pain subdomain (coefficient −0.24, 95% CI [−0.35 to −0.13]). This correlated to an average of 6.5 lifetime quality-adjusted life years lost per patient, translating to an individual lifetime economic burden of $323,292 and a societal burden of $38.8 billion.
Conclusion |
These results demonstrate that PN is associated with significant quality-of-life impairment, similar to the level of other chronic systemic conditions. PN is also associated with a substantial individual economic burden, emphasizing the necessity of research on effective treatment options.
Le texte complet de cet article est disponible en PDF.Key words : chronic pruritus, disease burden, economic burden, epidemiology, health utility, itch, prurigo nodularis, pruritus, quality of life
Abbreviations used : HUI3, PN, QALY, QoL
Plan
Drs Semenov and Kwarta are cofirst authors. |
|
Funding sources: Dr Kwatra received a research grant from Galderma and the Skin of Color Society and received a Medical Dermatology Career Development Award from the Dermatology Foundation. |
|
IRB approval status: This study was approved by the Johns Hopkins Institutional Review Board (IRB00157834). |
|
Reprints not available from the authors. |
Vol 86 - N° 3
P. 573-580 - mars 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?